These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17508494)

  • 21. Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses.
    Burnett TJ; English JC; Ferris LK
    J Drugs Dermatol; 2010 Aug; 9(8):1022-4. PubMed ID: 20684157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression in actinic keratoses: pharmacological modulation by imiquimod.
    Lysa B; Tartler U; Wolf R; Arenberger P; Benninghoff B; Ruzicka T; Hengge UR; Walz M
    Br J Dermatol; 2004 Dec; 151(6):1150-9. PubMed ID: 15606509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Innovative uses of imiquimod.
    Vender RB; Goldberg O
    J Drugs Dermatol; 2005; 4(1):58-63. PubMed ID: 15696986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mechanisms of imiquimod indirect antiviral activity].
    Hober D; Ajram L; Chehadeh W; Lazrek M; Goffard A; Dewilde A; Wattré P
    Ann Biol Clin (Paris); 2005; 63(2):155-63. PubMed ID: 15771973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
    Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
    J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of topical immune response modifiers in skin cancer.
    Woodmansee C; Pillow J; Skinner RB
    Drugs; 2006; 66(13):1657-64. PubMed ID: 16978032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery.
    Thomsen LL; Topley P; Daly MG; Brett SJ; Tite JP
    Vaccine; 2004 Apr; 22(13-14):1799-809. PubMed ID: 15068864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune response modification: imiquimod.
    Tyring S
    Australas J Dermatol; 1998 Nov; 39 Suppl 1():S11-3. PubMed ID: 9842095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imiquimod inhibits the differentiation but enhances the maturation of human monocyte-derived dendritic cells.
    Zhu KJ; Cen JP; Lou JX; Wang Q; Zhang X; Xu Y; Chen XZ; Cheng H
    Int Immunopharmacol; 2009 Apr; 9(4):412-7. PubMed ID: 19185063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential.
    Stanley MA
    Clin Exp Dermatol; 2002 Oct; 27(7):571-7. PubMed ID: 12464152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod.
    Wagner TL; Ahonen CL; Couture AM; Gibson SJ; Miller RL; Smith RM; Reiter MJ; Vasilakos JP; Tomai MA
    Cell Immunol; 1999 Jan; 191(1):10-9. PubMed ID: 9918682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod.
    Schön MP; Schön M
    Apoptosis; 2004 May; 9(3):291-8. PubMed ID: 15258460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insights into imiquimod's mechanisms of action.
    Martín-García RF
    J Drugs Dermatol; 2004; 3(3):247-9. PubMed ID: 15176157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609.
    Gibson SJ; Imbertson LM; Wagner TL; Testerman TL; Reiter MJ; Miller RL; Tomai MA
    J Interferon Cytokine Res; 1995 Jun; 15(6):537-45. PubMed ID: 7553223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells.
    Burns RP; Ferbel B; Tomai M; Miller R; Gaspari AA
    Clin Immunol; 2000 Jan; 94(1):13-23. PubMed ID: 10607486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imiquimod: mode of action.
    Schön MP; Schön M
    Br J Dermatol; 2007 Dec; 157 Suppl 2():8-13. PubMed ID: 18067624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions.
    Sauder DN
    J Cutan Med Surg; 2004; 8 Suppl 3():3-12. PubMed ID: 15647861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.
    Redondo P; del Olmo J; López-Diaz de Cerio A; Inoges S; Marquina M; Melero I; Bendandi M
    J Invest Dermatol; 2007 Jul; 127(7):1673-80. PubMed ID: 17380112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The TLR7 agonist, imiquimod, increases IFN-beta production and reduces the severity of experimental autoimmune encephalomyelitis.
    O'Brien K; Fitzgerald D; Rostami A; Gran B
    J Neuroimmunol; 2010 Apr; 221(1-2):107-11. PubMed ID: 20138374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imiquimod-induced hypopigmentation following treatment of periungual verruca vulgaris.
    Edgar N; Pilkington S; Hogan DJ
    Cutis; 2018 Jun; 101(6):466-468. PubMed ID: 30063776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.